The presence of CD30 in the TME is thus a double-edged sword; while it promotes the survival of HRS cells, it also contributes to the recruitment and activation of regulatory T cells and other immune suppressive elements that further protect the tumor from immune surveillance. The gene discussed is TNFRSF8; the disease is neoplasm.